Structural basis of PROTAC cooperative recognition for selective protein degradation

Nature Chemical Biology

Volumn 13, Issue 5, 2017, Pages 514-521

  Gadd, Morgan S ^a   Testa, Andrea ^a   Lucas, Xavier ^a   Chan, Kwok Ho ^a   Chen, Wenzhang ^a   Lamont, Douglas J ^a   Zengerle, Michael ^a   Ciulli, Alessio ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRD2 PROTEIN; BRD3 PROTEIN; BRD4 PROTEIN; BROMODOMAIN INHIBITOR; ELONGIN B; ELONGIN C; HISTONE H4; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LYSINE; MZ1 PROTEIN; PENICILLAMINE; PROTEIN; TERNARY COMPLEX FACTOR; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; AT1 COMPOUND; BRD4 PROTEIN, HUMAN; DIPEPTIDE; ELONGIN; FUSED HETEROCYCLIC RINGS; MOLECULAR LIBRARY; MULTIPROTEIN COMPLEX; MZ1 COMPOUND; NUCLEAR PROTEIN; PROTEIN BINDING; TRANSCRIPTION FACTOR; UBIQUITIN PROTEIN LIGASE; VHL PROTEIN, HUMAN;

ARTICLE; BINDING AFFINITY; BINDING ASSAY; CHIMERA; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROPHOBICITY; ISOTHERMAL TITRATION CALORIMETRY; MASS SPECTROMETRY; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN PROTEIN INTERACTION; PROTEOLYSIS TARGETING CHIMERA; SITE DIRECTED MUTAGENESIS; STEREOSPECIFICITY; SURFACE AREA; THERMODYNAMICS; UBIQUITINATION; AMINO ACID SEQUENCE; CHEMISTRY; DRUG EFFECTS; METABOLISM; MOLECULAR LIBRARY; MOLECULAR MODEL; PHARMACOLOGY; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; CRYSTALLOGRAPHY, X-RAY; DIPEPTIDES; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MODELS, MOLECULAR; MULTIPROTEIN COMPLEXES; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEOLYSIS; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS; TRANSCRIPTION FACTORS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 85015018807     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.2329     Document Type: Article

References (42)

1. Huang, X., Dixit, V. M. Drugging the undruggables: Exploring the ubiquitin system for drug development. Cell Res. 26, 484-498 (2016).
2. Petzold, G., Fischer, E. S., Thomä, N. H. Structural basis of lenalidomide-induced CK1 degradation by the CRL4(CRBN) ubiquitin ligase. Nature 532, 127-130 (2016).
3. Matyskiela, M. E., et al. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Nature 535, 252-257 (2016).
4. Lai, A. C., Crews, C. M. Induced protein degradation: An emerging drug discovery paradigm. Nat. Rev. Drug Discov. 16, 101-114 (2016).
5. Sakamoto, K. M., et al. Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl. Acad. Sci. USA 98, 8554-8559 (2001).
6. Winter, G. E., et al. Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376-1381 (2015).
7. Zengerle, M., Chan, K.-H., Ciulli, A. Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS Chem. Biol. 10, 1770-1777 (2015).
8. Lu, J., et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22, 755-763 (2015).
9. Bondeson, D. P., et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11, 611-617 (2015).
10. Deshaies, R. J. Protein degradation: Prime time for PROTACs. Nat. Chem. Biol. 11, 634-635 (2015).
11. Toure, M., Crews, C. M. Small-molecule PROTACS: New approaches to protein degradation. Angew. Chem. Int. Edn Engl. 55, 1966-1973 (2016).
12. Lai, A. C., et al. Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angew. Chem. Int. Edn Engl. 55, 807-810 (2016).
13. Filippakopoulos, P., et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073 (2010).
14. Galdeano, C., et al. Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities. J. Med. Chem. 57, 8657-8663 (2014).
15. Frost, J., et al. Potent and selective chemical probe of hypoxic signalling downstream of HIF-hydroxylation via VHL inhibition. Nat. Commun. 7, 13312 (2016).
16. Zuber, J., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524-528 (2011).
17. Nicodeme, E., et al. Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119-1123 (2010).
18. Hon, W.-C., et al. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature 417, 975-978 (2002).
19. Min, J.-H., et al. Structure of an HIF-1alpha-pVHL complex: Hydroxyproline recognition in signaling. Science 296, 1886-1889 (2002).
20. Filippakopoulos, P., et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149, 214-231 (2012).
21. Tanaka, M., et al. Design and characterization of bivalent BET inhibitors. Nat. Chem. Biol. 12, 1089-1096 (2016).
22. Whitty, A. Cooperativity and biological complexity. Nat. Chem. Biol. 4, 435-439 (2008).
23. Douglass, E. F. Jr., Miller, C. J., Sparer, G., Shapiro, H., Spiegel, D. A. A comprehensive mathematical model for three-body binding equilibria. J. Am. Chem. Soc. 135, 6092-6099 (2013).
24. Eglen, R. M., et al. The use of AlphaScreen technology in HTS: Current status. Curr. Chem. Genomics 1, 2-10 (2008).
25. Roberts, J. M., Bradner, J. E. A bead-based proximity assay for BRD4 ligand discovery. Curr. Protoc. Chem. Biol. 7, 263-278 (2015).
26. Stebbins, C. E., Kaelin, W. G. Jr., Pavletich, N. P. Structure of the VHL-ElonginC-ElonginB complex: Implications for VHL tumor suppressor function. Science 284, 455-461 (1999).
27. Duda, D. M., et al. Structural insights into NEDD8 activation of cullin-RING ligases: Conformational control of conjugation. Cell 134, 995-1006 (2008).
28. Zhou, M., Li, Q., Wang, R. Current experimental methods for characterizing protein-protein interactions. ChemMedChem 11, 738-756 (2016).
29. Raina, K., et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc. Natl. Acad. Sci. USA 113, 7124-7129 (2016).
30. Bulatov, E., Ciulli, A. Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: Structure, assembly and small-molecule modulation. Biochem. J. 467, 365-386 (2015).
31. Fischer, E. S., et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512, 49-53 (2014).
32. Fischer, E. S., Park, E., Eck, M. J., Thomä, N. H. SPLINTS: Small-molecule protein ligand interface stabilizers. Curr. Opin. Struct. Biol. 37, 115-122 (2016).
33. Tan, X., et al. Mechanism of auxin perception by the TIR1 ubiquitin ligase. Nature 446, 640-645 (2007).
34. Sheard, L. B., et al. Jasmonate perception by inositol-phosphate-potentiated COI1-JAZ co-receptor. Nature 468, 400-405 (2010).
35. Ito, T., et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345-1350 (2010).
36. Lu, G., et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343, 305-309 (2014).
37. Krönke, J., et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301-305 (2014).
38. Chamberlain, P. P., et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat. Struct. Mol. Biol. 21, 803-809 (2014).
39. Pommier, Y., Marchand, C. Interfacial inhibitors: Targeting macromolecular complexes. Nat. Rev. Drug Discov. 11, 25-36 (2011).
40. Thiel, P., Kaiser, M., Ottmann, C. Small-molecule stabilization of protein-protein interactions: An underestimated concept in drug discovery Angew. Chem. Int. Edn Engl. 51, 2012-2018 (2012).
41. Illendula, A., et al. Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBF-SMMHC delays leukemia in mice. Science 347, 779-784 (2015).
42. Waring, M. J., et al. Potent and selective bivalent inhibitors of BET bromodomains. Nat. Chem. Biol. 12, 1097-1104 (2016).